Vaccine candidates against hantaviruses, including Andes virus linked to recent outbreaks like the MV Hondius cluster, remain in preclinical or early Phase 1 stages as of October 2026, with no candidates positioned for regulatory approval or widespread availability by year-end. Promising single-dose mRNA platforms demonstrated full protection in hamster models and immunogenicity in mice, yet these require extensive human safety, dosing, and efficacy trials amid challenges like viral strain diversity and the low incidence of hantavirus pulmonary syndrome, which complicates large-scale studies. Trader consensus reflected in the 97.5% market-implied odds for no approval aligns with standard development timelines spanning multiple years and the absence of advanced candidates meeting FDA or equivalent criteria. Realistic shifts could arise from accelerated emergency authorization during a major outbreak or unexpected trial breakthroughs, though current surveillance data and model projections indicate low near-term probability.